Stomach Cancer Treatments: A Growing Market with Big Challenges

The market for stomach cancer treatments is growing fast. It was worth $5. 51 billion in 2024 and is expected to reach $12. 64 billion by 2030. This growth is driven by new drugs and therapies. The demand for affordable and painless treatments is also increasing. The aging population is another factor, as older people are more likely to get stomach cancer. Stomach cancer is a big problem worldwide. The World Health Organization reports about 1 million new cases each year. Nearly 800, 000 people die from it annually. This makes it one of the top five causes of cancer-related deaths. While the number of cases is declining in Western countries, it is rising in Asia and Latin America.Late diagnosis is a major challenge. In many places, stomach cancer is found too late for effective treatment. This is especially true in low-resource settings. Less than 10% of cases are diagnosed at an early stage outside of East Asia. This leads to low survival rates. The COVID-19 pandemic made things worse, with diagnoses dropping by 40% in South Asia. Immunotherapy is becoming a standard treatment. It has shown promising results, extending survival rates. Drugs like pembrolizumab and nivolumab are now commonly used. Biomarkers like PD-L1 are being used to select patients for treatment. Many countries are revising their guidelines to include immunotherapy. Several big companies are involved in this market. Pfizer, Novartis, Eli Lilly, and others are key players. The market is segmented by treatment type, cancer type, and region. North America, Europe, and Asia-Pacific are the main regions covered.